Biomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung Cancer

Durham: Biomarck Pharmaceuticals, Ltd recently announced that a Phase 2 clinical study in advanced NSCLC has commenced. This study at 10 sites in India compares standard of care therapy (SOC; pemetrexed and carboplatin) alone to SOC plus BIO-11006. This trial will evaluate the safety and efficacy of Biomarck’s novel, patented, MARCKS protein inhibitor in a controlled trial.

Read Also: Roche wins Japan approval for personalised cancer drug Rozlytrek

Commenting on the same, Dr Brian Dickson,Biomarck's CEO said,“Although advances have been made recently in the treatment of advanced NSCLC especially with immunotherapy, the five year survival rate remains disappointingly low. These immunotherapeutic agents have significant side effects and quality of life remains a critical issue to both patients and their treating oncologists. Animal studies have shown the ability of BIO-11006 to reduce primary tumor size, prevent the development of secondary tumors and act synergistically with other chemotherapeutic agents."

"The side effect profile in over 200 patients in previous clinical studies has demonstrated an encouraging safety database where only cough and headache were more common than placebo. Furthermore animals with NSCLC treated with BIO-11006 did not lose weight whereas those untreated lost 30% bodyweight within 3 weeks. The initiation of this clinical study represents a significant milestone for Biomarck as we progress to clinically develop our patented portfolio in diseases, such as non small cell lung cancer (NSCLC) that cause significant morbidity and mortality. This represents a first in class therapy," Brian added.

Read Also: Pfizer receives USFDA approval for biosimilar to Avastin